Forest memantine neuropathic pain trial fails
Executive Summary
Forest is reviewing plans to develop diabetes agent memantine for neuropathic pain after Phase III clinical trial "failed to demonstrate a statistically significant difference versus placebo," Forest says. An earlier pivotal trial met endpoints for nocturnal pain in patients with diabetic neuropathy. Memantine is one product Forest is counting on to support long-term growth following loss of exclusivity for Celexa (1"The Pink Sheet" April 28, p. 33)...